此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Efficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora

2015年5月27日 更新者：NovaBay Pharmaceuticals, Inc.

A Multicenter Randomized, Double-Masked Study Comparing the Efficacy of Novabay iLid Cleanser Versus Vehicle on Ocular Skin Flora

This study is designed to evaluate the effect of Novabay iLid Cleanser, as compared to its Vehicle, on the ocular skin flora.

In the pre-randomization phase, subjects will receive a single application of open-label NovaBay iLid Cleanser.

In the randomization phase of Stages 1 and 2, subjects will self-treat with masked Investigational Product twice daily for ten (10) days.

研究概览

地位

未知

条件

干预/治疗

详细说明

This is an adaptive design, randomized, double-masked, vehicle-controlled, multicenter, parallel group study with two treatment arms: NovaBay iLid Cleanser ("Cleanser") and Cleanser Vehicle ("Vehicle").

The study will be conducted in two Stages, each preceded by a pre-randomization phase. Randomization of Cleanser:Vehicle will be 1:1 and 2:1 in Stages 1 and 2 respectively.

In the pre-randomization phase for Stages 1 and 2, subjects who meet all inclusion and no exclusion criteria will be evaluated by clinical examination at a single visit prior to having ocular skin specimens taken before and after treatment with open-label Cleanser.

In the randomization phase for both Stages 1 and 2, subjects who meet all inclusion and no exclusion criteria will be randomized and evaluated at three visits:

  • Visit 1: Screening, Day 1
  • Visit 2: Day 11 (+2) End of Treatment (EOT)
  • Visit 3: Day 18 (±2) Post Treatment Evaluation/Exit Subjects will have ocular skin specimens taken at Visit 1, Day 1. The specimens will be collected before and 20 minutes after the first application of the study Investigational Product performed by study personnel.

研究类型

介入性

注册 (预期的)

100

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 美国
    • Arizona
      • Phoenix、Arizona、美国、85032
        • 招聘中
        • Ophthalmic Research Consultants of Arizona
        • 接触：
        • 首席研究员：
          • Arthur Epstein, OD
    • California
      • San Leandro、California、美国、94577
        • 招聘中
        • Turner Eye Institute
        • 接触：
    • North Carolina
      • Winston Salem、North Carolina、美国、27101
        • 招聘中
        • James D. Branch, MD
        • 接触：
        • 首席研究员：
          • James Branch, MD

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

6年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Male or female, of any race, at least 6 years of age.

  • Must be eligible for a recommendation to use eye lid cleansing/scrubs for:

    • Signs of acute or chronic blepharitis, such as eye lid debris (sleeves, collorates, flakes, crusting) requiring eye lid cleansing/scrubs, and/or
    • Signs consistent with mild, moderate, or severe meibomian gland disease (MGD) such as dilated and blocked glands with inspissated secretions sluggish or stagnant upon expression.
  • Must be able to read, understand and sign an informed consent form that has been approved by an Institutional Review Board/Ethics Committee. If subject is less than 18 years of age, the informed consent must be signed and dated by subject's legally authorized representative (parent or guardian). Assent to participate should also be obtained from subjects under 18 years of age if required by local regulation.
  • Must agree to comply with the visit schedule and other requirements of the study. The parent or guardian must agree to ensure compliance of subjects less than 18 years of age.
  • Must agree to remove contact lenses, if applicable, for 15 minutes before and after application of the study Investigational Product.
  • Must agree for the duration of the study to refrain from use of makeup/cosmetic products used around the eye(s) such as eye liner, mascara, and/or shadow, foundation or powder. Use of such products is allowed if the eyelid skin area is avoided.

Exclusion Criteria:

  • Presence of signs and symptoms of bacterial or allergic conjunctivitis or allergic dermatitis at the Day 1 Visit.
  • Suspected fungal, viral, Chlamydia or Acanthamoeba infection based on clinical diagnosis.
  • Visual acuity not correctable to 1.0 LogMAR or better (equivalent to Snellen 20/200) in either eye using either a Snellen or ETDRS chart.
  • Use of any topical ocular medications including tear substitutes during study participation.
  • Use of any preserved or non-preserved glaucoma medications during the 14 days prior to Visit 1 and anticipated use during study participation.
  • Presence of nasolacrimal duct obstruction.
  • Presence of a punctal plug in either eye.
  • Any systemic or ocular disease or disorder, complicating factors or structural abnormality that would negatively affect the conduct or outcome of the study.
  • Presence of active inflammation and/or active structural change in the cornea, iris or anterior chamber at the Day 1 visit.
  • Use of any topical ocular or oral antimicrobial agent within the 3 days prior to Day 1 visit.
  • Use of topical ocular corticosteroids or non-steroidal topical ocular anti-inflammatories (NSAIDs), within 3 days prior to study entry and during the trial.
  • Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%) in either eye during the trial.
  • Any current immunosuppressive disorder (e.g., HIV positive), or use of immunosuppressive therapy (including chemotherapy).
  • Participation in any other investigational clinical study within 30 days prior to study enrollment.
  • Any subject who is on staff at the investigational site or is a family member of staff personnel.
  • Additionally, the Investigator or Medical Monitor may declare any subject ineligible for a sound medical reason.

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：支持治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：双倍的

武器和干预

参与者组/臂
干预/治疗
有源比较器：iLid Cleanser (Avenova)
iLid Cleanser - applied 2 times per day for 10 days
设备：iLid Cleanser
Application of iLid Cleanser to reduce bacterial load on the lid and lash margins
其他名称：
  • 阿韦诺娃
安慰剂比较：iLid Cleanser Vehicle
iLid Cleanser Vehicle - applied 2 times per day for 10 days
设备：iLid Cleanser
Application of iLid Cleanser to reduce bacterial load on the lid and lash margins
其他名称：
  • 阿韦诺娃

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Microbiological efficacy
大体时间：20 minutes after application of test article
Quantitative assessment of numbers of recoverable bacteria before versus after application of test article
20 minutes after application of test article

次要结果测量

结果测量
措施说明
大体时间
Ocular Signs
大体时间：Assessed on Visit 1(Day 1), Visit 2 (Day 11) and Visit 3 (Day 18)
lid erythema, lid swelling, lid crusting and debris on lashes, bulbar and palpebral conjunctival injection, and meibomian gland secretions (after expression)
Assessed on Visit 1(Day 1), Visit 2 (Day 11) and Visit 3 (Day 18)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

NovaBay Pharmaceuticals, Inc.

调查人员

  • 研究主任：David W. Stroman, Ph.D.、NovaBay Pharmaceuticals, Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2015年5月1日

初级完成 (预期的)

2016年1月1日

研究完成 (预期的)

2016年5月1日

研究注册日期

首次提交

2015年5月26日

首先提交符合 QC 标准的

2015年5月27日

首次发布 (估计)

2015年5月28日

研究记录更新

最后更新发布 (估计)

2015年5月28日

上次提交的符合 QC 标准的更新

2015年5月27日

最后验证

2015年5月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • CM-01-14

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅